The binding of thrombopoietin (TPO) to its cognate receptor, Mpl, triggers a series of intracellular signal transductions to stimulate mature megakaryocytes that respond by increasing platelet production. TPO cDNA was cloned in 1994, and the product of TPO was described as consisting of two domains, a N-terminal cytokine domain (150 amino acids) and a larger C-terminal domain (203 amino acids). 1, 2) The N-terminal TPO is responsible for binding to its receptor, leading to dimerization in which two receptor molecules bind one ligand at the extracellular domain of Mpl (Mpl-EC).
MATERIALS AND METHODS
Materials A pMal protein expression and purification system, including pMal-c2X, MBP antibody, and amylose resin, were purchased from New England Biolabs (Beverly, MA, U.S.A.). Bacterial strain BL21(DE3)pLysS was purchased from Novagen (Madison, WI, U.S.A.). Recombinant mouse TPO was obtained from Sigma Chemical (St. Louis, MO, U.S.A.).
Construction of the Expression Plasmid pMal-Mpl-EC
The DNA fragment encoding Mpl-EC (26-491) without the signal peptide was amplified by PCR using previously constructed plasmid pET-TPOR-EN 7) as a template, and the sense primer 5Ј-CCGGAA TTCATGAGC CAAGAT-GTCTCCTTGCTG-3Ј and antisense primer 5Ј-ATA GTC-GACTTA AGTTGGGTCCGACCACGAGCT-3Ј. EcoRI and SalI (underlined) were introduced into the sense and antisense primers, respectively. The PCR product was subcloned into EcoRI-and SalI-digested expression vector pMal-c2X. The construct was confirmed by nucleotide sequencing and was used to transform E. coli strain BL21(DE3)pLysS.
Expression and Purification of MBP-Mpl-EC E. coli strain BL21 (DE3) expressing MBP-Mpl-EC was grown in LB medium containing ampicillin 0.1 mg/ml to an A 600 of 0.7 at 37°C. The expression was induced with 0.5 mM IPTG for 3 h at 30°C. Cells were collected by centrifugation and resuspended in a binding buffer containing 20 mM Tris, pH 7.4, 150 mM NaCl, 0.1 mM PMSF, 1 mM EDTA, and 0.5 mM dithiothreitol, and frozen at Ϫ80°C. The bacteria was thawed at 37°C and lysed by sonication. The soluble faction containing MBP-Mpl-EC fusion protein was loaded on a prepacked amylose affinity column, washed with 3 column volumes with a buffer of 20 mM Tris, pH 7.4, and 150 mM NaCl. Elution was performed with the same buffer supplemented with 10 mM maltose.
Electrophoresis and Western-Blot Analysis Protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% polyacrylamide gel. After electrophoresis, the gel was soaked in transfer buffer (48 mM Tris, 39 mM glycine, 0.037% w/v SDS in 20% v/v methanol). Protein was transferred to PVDF membrane using a Hoefer SemiPhor semi-dry transfer unit (Pharmacia, Uppsala, Sweden). The PVDF membrane was blocked by adding 1% bovine serum albumin (BSA) in Tris-buffered Tween-20 (TBT) overnight at 4°C, followed by incubation with rabbit polyclonal serum raised against MBP diluted in blocking solution. Immunoreactive materials were detected using alkaline phosphatase-conjugated goat anti-rabbit antibodies (MBI Fementas, 1 : 10000).
Dot-Blot Assay Binding interaction between TPO and purified MBP-Mpl-EC was performed using a dot blot analy-sis. TPO was diluted in PBS buffer, pH 7.4, at concentration ranging from 12.5 ng/ml to 200 ng/ml, 5 ml each sample was spotted onto a PVDF membrane using a dot-blot filtration apparatus, and the membrane was blocked with 1% BSA in TBT buffer for 1 h. The membrane was then incubated with purified MBP-Mpl-EC (0.5 mg/ml) in blocking buffer overnight at 4°C. After washing with TBT buffer, the membrane was incubated with anti-MBP polyclonal antibody for 2 h at room temperature. After extensively washing the membrane again with TBT buffer, bound protein was detected using alkaline phosphatase-conjugated goat anti-rabbit antibodies.
Surface Plasmon Resonance Analysis The procedures were essentially in accordance with the Affinity Sensor instruction manual (Affinity Sensors, Cambridge, U.K.). Briefly, the cuvette was equilibrated at 25°C in PBS/T (10 mM phosphate, 2.7 mM potassium chloride, 137 mM sodium chloride, 0.05% Tween 20) for 10 min, followed by activation for 7 min with a freshly prepared NHS/EDC mixture. MBP-Mpl-EC was added and left for 10 min. Uncoupled MBP-Mpl-EC was washed out with PBS/T. Any nonreacted carboxyl groups were deactivated with 1 M ethanolamine, pH 8.5. Binding assays were performed in 100 ml of PBS (120 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4). Dissociation was performed by replacing the TPO with 100 ml of PBS. The cuvette was regenerated by washing with 20 mM HCl for 1 min. Both k ass and k diss rate constants were calculated according to the first-order equation:
where R t is the response at time t; R o is the initial response; E is the extent of the response and k on is the on-rate constant.
RESULTS AND DISCUSSION

Construction and Expression of MBP-Mpl-EC Fusion Protein
The cDNA encoding Mpl-EC lacking it signal peptide was cloned into the pMal-c2X vector, downstream and in frame with the malE gene encoding MBP to give the construct pMal-Mpl-EC (Fig. 1) . After sequencing the clone insert, it showed an identical sequence to that previously described for Mpl cDNA (GenBank Accession No. NM 005373). A construct was used to transform E. coli BL21(DE3)pLysS as a bacterial expression host. Different concentrations of IPTG (0.5, 1, 2, 5 mM) were compared for inducing the expression of protein, and induction with 0.5 mM IPTG yielded a higher level of expression (data not shown). In the cellular lysate of E. coli, the band of 90 kDa, corresponding to MBP-Mpl-EC, was clearly shown on SDS-PAGE after Coomassie blue staining (Fig. 2A) . The bacterial lysate was subjected to centrifugation to analyze the solubility of the MBP-Mpl-EC fusion protein. About 50% of the protein produced with pMal-Mpl-EC was present in the soluble fraction, whereas almost half appeared to be insoluble (data not shown). In an attempt to minimize the formation of inclusion bodies and increase the yield of the soluble fraction, the growth conditions of the bacteria were altered so that the temperature of the incubation was decreased from 30 to 25°C. However, the expression of soluble protein did not increase with incubation at the lower temperature (data not shown).
Purification of MBP-Mpl-EC Fusion Protein
The soluble form of MBP-Mpl-EC from the crude extract fraction was directly purified using an amylose-agarose column. After elution of the fusion protein from the column, the quantity of the purified protein was determined using the Bradford assay (Bio-Rad) with BSA as a standard. The total amount of protein recovered was estimated to be 10 mg per liter of bacterial culture. The purified protein was run on 10% polyacrylamide gel along with the samples of lysate and crude extract. Figure  2 shows a band at 90 kDa, which is the expected size of the fusion protein. The purity of MBP-Mpl-EC was estimated to be greater than 85% (Fig. 2A) . A band of the expected size was detected in Western blotting by anti-MBP antibodies directed against the fusion protein (Fig. 2B) .
Binding of TPO to Recombinant MBP-Mpl-EC To evaluate whether the recombinant MBP-Mpl-EC retained its biochemical function, the interaction between TPO and MBP-Mpl-EC was verified in vitro using a dot-blot assay. An equal volume of two-fold serially diluted of TPO was spotted 220 Vol. 27, No. 2 onto a PVDF membrane and incubated with the purified MBP-Mpl-EC or MBP, and binding was monitored by treating the dot-blot with the MBP-specific antibody. Quantification results are presented in Fig. 3 , indicating that the fusion protein had saturable high-affinity binding for TPO, whereas no nonspecific binding occurred in the control experiment with MBP.
We next determined the rate constants of binding association (k ass ) and dissociation (k diss ) between MBP-Mpl-EC and TPO using the IAsys Affinity Biosensor. The purified MBPMpl-EC protein was immobilized covalently to the surface of a carboxymethyl dextran cuvette and hybridized with TPO at varied concentrations, ranging from 0.41 mM to 2.06 mM. Figure 4 , respectively, calculated using the FASTfit program algorithm. 8, 9) From the ratio of the respective constants, a K(D) value of 514 nM was determined. The experiment was repeated in reverse orientation, with TPO immobilized to an aminosilane cuvette and differ- , and K(D)ϭ490.4 nM (data not shown). Furthermore, no nonspecific binding was evident when MBP was used as a negative control (data not shown).
In conclusion, the successful production of soluble human recombinant Mpl-EC, expressed in a prokaryotic system, has been achieved for the first time. The specificity of the binding was further demonstrated by the interaction between TPO and MBP-Mpl-EC or MBP using a dot-blot assay. The purified MBP does not bind any TPO protein, indicating that the interaction is mediated through the Mpl-EC of MBP-Mpl-EC. The real-time sensorgram with a change in RU over time showed a strongly concentration-dependent binding of TPO to the surface-immobilized MBP-Mpl-EC. These observations are conclusive evidence that the MBP-Mpl-EC is correctly folded. The interaction between MBP-Mpl-EC and TPO was monitored by surface plasmon resonance using an IAsys Affinity Biosensor. MBP-Mpl-EC was immobilized on the cuvette surface via NHS/EDC chemistry. To determine the k ass and k diss values of TPO for MBP-Mpl-EC, TPO was injected over immobilized MBP-Mpl-EC at concentrations ranging from 0.41 to 2.06 mM.
